Acquired Athyrium Capital Management in Dec 2023
Company logo

RVLP - RVL Pharmaceuticals plc

NASDAQ -> Healthcare -> Biotechnology
Bridgewater, United States
Type: Equity

RVLP price evolution
RVLP
(in millions $) 30 Jul 2023 1 May 2023 31 Jan 2023 30 Oct 2022
Current assets
Cash
Short term investments
Net receivables $1.93 $1.88 $3.03 $3.28
Inventory $1.36 $0.21 $0.78 $0.62
Total current assets $25.75 $38.35 $56.98 $70.91
Long term investments
Property, plant & equipment $3.81 $3.01 $1.79 $1.38
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $85.4 $111.11 $128.51 $155.35
Current liabilities
Accounts payable $2.53 $2.63 $2.41 $7
Deferred revenue
Short long term debt
Total current liabilities $68.39 $16.41 $19.72 $21.48
Long term debt $0.01 $53.05 $55.52 $55.92
Total noncurrent liabilities
Total debt
Total liabilities $69.08 $71.11 $77.42 $86.81
Shareholders' equity
Retained earnings -$604.72 -$580.83 -$569.22 -$550.9
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2023 31 Jan 2022 31 Jan 2021 31 Jan 2020
Current assets
Cash
Short term investments
Net receivables $3.03 $2.13 $26.41 $43.91
Inventory $0.78 $0.84 $17.93 $21.3
Total current assets $56.98 $59.38 $173.15 $172.63
Long term investments
Property, plant & equipment $1.79 $2.23 $30.81 $35.22
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $128.51 $144.67 $370.95 $463.25
Current liabilities
Accounts payable $2.41 $3.78 $6.77 $8.49
Deferred revenue
Short long term debt
Total current liabilities $19.72 $20.11 $55.78 $75.94
Long term debt $55.52 $43.8 $219.53 $267.99
Total noncurrent liabilities
Total debt
Total liabilities $77.42 $67.94 $277.09 $348.55
Shareholders' equity
Retained earnings -$569.22 -$517.53 -$452.61 -$373.02
Other shareholder equity $1.7 -$2.23 -$2.23
Total shareholder equity
(in millions $) 30 Jul 2023 1 May 2023 31 Jan 2023 30 Oct 2022
Revenue
Total revenue $8.26 $8.83 $9.81 $10.02
Cost of revenue
Gross Profit $6.31 $6.53 $7.25 $7.5
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $14.43 $16.82 $18.48 $20.42
Operating income
Income from continuing operations
EBIT
Income tax expense -$0.11 $0.06 -$0.28 $0.06
Interest expense -$3.16 -$7.38 -$1.92 $3.93
Net income
Net income -$23.89 -$11.61 -$18.32 -$14.45
Income (for common shares)
(in millions $) 31 Jan 2023 31 Jan 2022 31 Jan 2021 31 Jan 2020
Revenue
Total revenue $49.72 $177.88 $240.03
Cost of revenue
Gross Profit $40.27 $103.4 $128.4
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $83.04 $101.66 $125.35
Operating income
Income from continuing operations
EBIT
Income tax expense -$0.02 -$4.7 -$27.12
Interest expense -$0.25 -$14.4 -$18.21
Net income
Net income -$51.69 -$79.59 -$270.9
Income (for common shares)
(in millions $) 30 Jul 2023 1 May 2023 31 Jan 2023 30 Oct 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$2.18 -$1.23 $0.13 $0.3
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$5.32 -$4.86 $41.78 $40.39
Effect of exchange rate
Change in cash and equivalents -$25.38 -$11.9 $4.1 $19.31
(in millions $) 31 Jan 2023 31 Jan 2022 31 Jan 2021 31 Jan 2020
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $0.13 $116.45 -$3.08 -$4.02
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $41.78 -$135.33 $3.68 -$4.69
Effect of exchange rate $0.17
Change in cash and equivalents $4.1 -$73.61 $18.19 $25.03
Fundamentals
Market cap $238.54K
Enterprise value N/A
Shares outstanding 99.39M
Revenue $36.92M
EBITDA N/A
EBIT N/A
Net Income -$68.27M
Revenue Q/Q -2.25%
Revenue Y/Y N/A
P/E ratio -0.00
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 0.01
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.69
ROA -56.84%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 0.38
Quick ratio 0.36